Neoadjuvant chemotherapy and concurrent chemoradiation in the treatment of avanced cervical cancer

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3525-3533

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Cionini, Luca ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cervical cancer; Chemotheraphy; Radiation; Surgery

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MESNA; METHOTREXATE; MITOMYCIN C; NAVELBINE; VINCA ALKALOID; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL POPULATION; CLINICAL TRIAL; CLONOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL TIME; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS;

EID: 0035568894     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Global cancer statistics
2. Radical hysterectomy for invasive cervical cancer. A 25-year prospective experience with the Miami technique
3. Radiation therapy of cervical cancer. New developments
4. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer
5. Advanced stage IIIB cancer of the cervix treatment by hyperthermia and radiation
6. Neutron therapy in cervical cancer: Results of a phase III RTOG study
7. A comparison of intracavitary versus interstitial irradiation in the treatment of cervical cancer
8. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: Is there an optimal fractionation schedule?
9. The effect of treatment duration in the local control of cervix cancer
10. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study
11. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome
12. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy
13. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: Analysis of two different methods
14. Clinical dose response curves of human malignant epithelial tumours
15. Chemotherapy in advanced and recurrent cervical cancer: A review
16. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix
17. Cisplatin-ifosfamide as neoadjuvant chemotherapy in stage IIIB cervical squamous-cell carcinoma
18. Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2bN1, T3b, MO)
19. Induction chemotherapy followed by radical surgery in cervical cancer
20. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival
21. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix
22. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: A preliminary report
23. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer
24. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma: A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
25. Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma
26. Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancer
27. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: A pilot study and phase III randomized trial
28. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy
29. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix
30. Neoadjuvant chemotherapy in locally advanced cervical cancer: Two randomised studies
31. Neoadjuvant chemotherapy (NACT) in locally advanced uterine cervical cancer (LAUCC): Correlation between pathological response and survival
32. Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix
33. Combination chemotherapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
34. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix
35. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer
36. Multiple tumour marker assay in advanced cervical cancer: Relationship to chemotherapy response and clinical outcome
37. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix
38. Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma
39. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma
40. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer
41. Neoadjuvant chemotherapy followed by radiotherapy should not be a standard approach for locally advanced cervical cancer
42. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide, and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix
43. The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer
44. The hazard of accelerated tumor clonogen repopulation during radiotherapy
45. Chemotherapy and radiation therapy for cervical cancer
46. Mechanisms of crossresistance between radiation and antineoplastic drugs
47. Neoadjuvant chemotherapy before surgery in cervical cancer
48. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix
49. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: The final results
50. Neoadjuvant chemotherapy for locally advanced cervical cancer-where does it stand? A review
51. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri
52. Neoadjuvant chemotherapy (Nch) in stage IIB cervical carcinoma: Results of a four arms randomized trial
53. Neoadjuvant chemotherapy (NACT) and radical surgery (RS) vs exclusive radiotherapy (RT) in locally advanced squamous cell cervical cancer (LASCCC). Results from the Italian Multicenter Randomized Study
54. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer
55. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-cancer
56. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
57. Neoadjuvant chemotherapy with cisplatin, ifosfamide, and paclitaxel for locally advanced squamous-cell cervical cancer
58. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: The experience of Monza
59. A multicenter randomized trial on neoadjuvant chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) vs IP followed by surgery for locally advanced squamous cell cervical cancer (SCCC)
60. Locally advanced cervical adenocarcinoma: Is there a place for Chemo-surgical treatment?
61. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma
62. Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix
63. Chemoradiation interactions: Potential of newer chemotherapeutic agents
64. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis
65. Hydroxyurea: A radiation potentiator in carcinoma of the uterine cervix - A randomized double-blind study
66. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a Gynecologic Oncology Group trial
67. Neoadjuvant chemotherapy to radiation and concurrent chemoradiation for locally advanced squamous cell carcinoma of the cervix: A review of the recent literature
68. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study
69. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
70. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
71. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
72. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy. Report of a phase III Intergroup Study
73. Chemoradiotherapy: The new standard care for invasive cervical cancer
74. Chemoradiation for carcinoma of the cervix: Advances and opportunities
75. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinoma. Ten-year treatment results of RTOG 79-20
76. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials
77. A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group
78. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
79. Combination of taxanes with radiation: Preclinical studies
80. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
81. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumors in vivo
82. Simultaneous paclitaxel and radiotherapy: Initial clinical experience in lung cancer and other malignancies
83. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer
84. Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri
85. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix?